Short answer
Kimberly-Clark (KMB) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $4.1B (down 0.4% year over year) with net income of $1.8B.
Q3 2026 key financials · XBRL
- Revenue
- $4.1B
- −0.4% YoY · −1.3% QoQ
- Net income
- $1.8B
- +302.0% YoY · +419.7% QoQ
- Operating margin
- 12.5%
- Gross margin
- 34.9%
- EPS (diluted)
- $5.38
- +301.5% YoY · +422.3% QoQ
Source: XBRL data from the Kimberly-Clark (KMB) Q3 2026 10-Q on SEC EDGAR. USD.
Kimberly-Clark Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $4,134M, down 0.4% YoY from $4,150M; organic sales declined 1.3%
- Gross margin 34.9% vs 36.0% YoY; adjusted gross margin 35.5% vs 36.8%
- North America strongest: sales $2,738M, up 0.9%; International Personal Care weakest, sales $1,396M, down 2.8%
- Operating cash flow $2.4B nine-month, up from $1.8B; capital spending $1.0B vs $741M
- China diaper disruption remains a near-term headwind; incremental Middle East input costs estimated at approximately $250 for the year
Risk Factors
- Kenvue Acquisition integration: complex system consolidation could disrupt demand fulfillment and financial reporting
- OTC product safety: oral phenylephrine removal could require reformulation or withdrawal of Sudafed PE and Tylenol Cold & Flu
- Regulatory compliance: expanded OTC operations require cGMP compliance across company and third-party manufacturing facilities
- Supply continuity: transition away from J&J manufacturing could increase defects, quality issues, and delivery costs
- Indemnification exposure: talc claims outside the United States and Canada remain Kenvue’s responsibility with unquantifiable liability
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Kimberly-Clark quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.